WALLSTRASSE 16, BERLIN, 2M
SPA Amendment Reduces Share Issuance to Beckley Psytech Shareholders
Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
Announce Positive Topline Data from Phase 2b Study of BPL-003 for Treatment-Resistant Depression
To Combine Creating a Global Leader in Psychedelic Mental Health Therapies
Shareholder votes
Q2
Q1
FY 2024
Amended Quarterly Report
Q3
FY 2023
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Effectiveness Notice
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence